Navigation Links
Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
Date:4/30/2009

SEATTLE, April 30 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the first quarter ended March 31, 2009, after the close of market on May 7, 2009. The company's earnings conference call will take place May 7, 2009, at 2 p.m. PDT (5 p.m. EDT).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

Both live events will be available for viewing on Trubion's website at http://investors.trubion.com.

First-Quarter 2009 Earnings Conference Call: 2 p.m. PDT (5 p.m. EDT), May 7, 2009

Trubion will host a conference call and webcast to discuss its financial results in the first quarter, which ended March 31, 2009. The call will be held May 7 at 2 p.m. PDT (5 p.m. EDT). The live event will be available on Trubion's website at http://investors.trubion.com, or by calling (877) 795-3638 or (719) 325-4816. A replay of the discussion will be available from Trubion's website or by calling (888) 203-1112 or (719) 457-0820 and entering 6540657. The telephone replay will be available until midnight, May 14, 2009.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com.

    Contact:
    Jim DeNike
    Senior Director, Corporate Communications
    Trubion Pharmaceuticals, Inc.
    (206) 838-0500
    jdenike@trubion.com
   http://www.trubion.com

    Waggener Edstrom Worldwide Healthcare
    Amy Petty
    Senior Account Executive
    (617) 576-5788
    amyp@waggeneredstrom.com

TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
2. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
3. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
4. Trubion Announces Presentations at Upcoming Investor Conferences
5. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
6. Trubion Announces Presentations at Upcoming Investor Conferences
7. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
8. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
9. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
10. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
11. Trubion Announces Presentations at April/May Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Customers often prefer ... again and again. METTLER TOLEDO has released two new videos that show how ... integration of the ACT350 into Siemens and Allen Bradley PLCs is easy and ...
(Date:5/21/2017)... ... May 20, 2017 , ... ... the lengthy trial and error process by finding the right antidepressant faster. ... strengthen the doctor-patient relationship through a personalized approach to treatment. , ...
(Date:5/18/2017)... ... May 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great Point ... continues to grow. CSM has doubled in size over the past six months ... growth strategy. , Roger Gasper joins CSM as Chief Financial Officer. Roger has ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... varying industries, including food and dairy, munitions, and pharmaceutical/biotech, recently introduced The Revolution ... ease of use. The improvement in technology comes on the heels of HOLLOWAY’s ...
Breaking Biology Technology:
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
(Date:3/22/2017)... NEW YORK , March 21, 2017 /PRNewswire/ ... Customer Marketing Cloud used by retailers such as ... in its platform — Product Recommendations and Replenishment. Using ... to give more personalized product and replenishment recommendations ... purchases, but also on predictions of customer intent ...
Breaking Biology News(10 mins):